术前循环11-氧代雄激素与局限性前列腺癌无转移生存相关
研究纳入前瞻性PROCURE队列中1793例未治疗及155例术前接受5α-还原酶抑制剂治疗的局限性前列腺癌患者,术前检测7种肾上腺11-氧代雄激素及其代谢物。中位随访93.8个月,多变量分析显示11β-羟基雄烯二酮、11-酮睾酮及其代谢物11-酮雄酮与无转移生存相关(P=.06、P=.03、P=.008),5α-还原酶抑制剂治疗影响其水平。
要点
- 术前11-氧代雄激素水平与局限性前列腺癌根治术后的无转移生存相关。
- 11-酮睾酮及其代谢物11-酮雄酮与无转移生存的关联有统计学意义。
- 5α-还原酶抑制剂治疗者11-氧代雄激素前体及活性雄激素蓄积、代谢物降低。
核心结论
- 术前循环11-氧代雄激素水平与接受根治性前列腺切除术的局限性前列腺癌患者的无转移生存相关,并受5α-还原酶抑制剂治疗影响。
研究设计与样本
- 前瞻性PROCURE队列研究,纳入1793例未治疗患者和155例术前接受5α-还原酶抑制剂治疗的患者,术前留取血浆,根治性前列腺切除术前采样。
- 用液相色谱-串联质谱法定量7种肾上腺11-氧代雄激素前体、活性11-氧代雄激素及其代谢物。
- 采用多变量Cox比例风险模型评估循环水平与预后因素、无病生存及无转移生存的关系。
主要发现
- 术后中位随访93.8个月,583例出现生化复发,104例发生转移,168例死亡。
- PSA >20 ng/mL及淋巴结阳性的患者中11-羟基睾酮和11-酮睾酮水平较高(P < .05)。
- 多变量分析未观察到11-氧代雄激素与无病生存的显著关联。
- 按四分位数建模,肾上腺11β-羟基雄烯二酮、主要的雄激素性11-酮睾酮及其代谢物11-酮雄酮与无转移生存相关(P = .06、P = .03、P = .008)。
- 接受5α-还原酶抑制剂的患者中观察到11-氧代雄激素前体和生物活性雄激素显著蓄积、代谢物水平降低(P < .001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Adrenal 11-oxygenated androgens may support cancer progression in men with prostate cancer owing to their abundance and androgenic potential. We hypothesized that preoperative circulating levels of 11-oxygenated androgens influence clinical outcomes in men with newly diagnosed localized prostate cancer. MATERIALS AND METHODS: We studied 1,793 treatment-naïve patients and 155 patients who received preoperative treatment with 5α-reductase inhibitors in the prospective PROCURE cohort, for which preoperative plasma samples were obtained prior to radical prostatectomy. Adrenal 11-oxygenated precursors, potent 11-oxygenated androgens and their metabolites (n=7), were quantified using liquid chromatography-tandem mass spectrometry. Circulating levels were evaluated in relation to prognostic factors, disease-free survival, and metastasis-free survival using multivariable Cox proportional hazards models. RESULTS: At a median follow-up of 93.8 months after surgery, 583 patients experienced biochemical recurrence, 104 developed metastatic disease, and 168 deceased. Higher levels of 11-hydroxytestosterone and 11-ketotestosterone were observed in men with PSA >20 ng/mL and positive nodal status (P < .05). In multivariable analyses, no significant association between 11-oxygenated androgens and disease-free survival was observed. Adrenal 11β-hydroxyandrostenedione, the predominant androgenic 11-ketotestosterone, and its metabolite 11-ketoandrosterone, modeled as quartiles, were associated with metastasis-free survival (P = .06, P = .03, and P = .008, respectively). Significant accumulation of 11-oxygenated androgen precursors and bioactive androgens, but reduced metabolite levels, was observed in patients on 5α-reductase inhibitors (P < .001). CONCLUSIONS: Preoperative circulating 11-oxygenated androgen levels are associated with metastasis-free survival in men with localized prostate cancer undergoing radical prostatectomy and are affected by 5α-reductase inhibitor treatment.
引用
- Dahmani C, Caron P, Simonyan D, et al. Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer. J Urol. 2022. PMID: 36373402. doi:10.1097/JU.0000000000003049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。